Phase I,dose escalation of LTX-315 in transdermally accessible tumours

• Research type

  Research Study

• Full title

  A phase I, open-label, multi-arm, multi-centre, multi-dose, dose escalation study of LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab, in patients with transdermally accessible tumours

• IRAS ID

  136379

• Contact name

  James Spicer

• Contact email

  james.spicer@kcl.ac.uk

• Sponsor organisation

  Lytix Biopharma AS

• Eudract number

  2013-002772-41

• Duration of Study in the UK

  4 years, 0 months, 1 days

• Research summary

  This is a phase I, open-label, multi-arm, multicentre, dose escalation study in patients with tumours accessible for injection (cutaneous, subcutaneous, lymph node and oral lesions) assessing the safety, PK and efficacy of different dosing regimens of LTX-315 as monotherapy. Safety and efficacy of LTX-315 will also be assessed in combination with ipilimumab or pembrolizumab.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  13/SC/0467

• Date of REC Opinion

  1 Oct 2013

• REC opinion

  Further Information Favourable Opinion